key: cord-0750685-y9wdz5i7 authors: Sahraian, Mohammad Ali; Azimi, Amirreza; Navardi, Samira; Ala, Sara; Moghadasi, Abdorreza Naser title: Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis date: 2020-08-29 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2020.102472 sha: 620f7bf00c083908262529fed5ee36401fac9a01 doc_id: 750685 cord_uid: y9wdz5i7 BACKGROUND: COVID-19 is increasingly expanding all over the world. People who have an underlying disease or taking immunosuppressive drugs are generally more likely to be infected than the others. Multiple sclerosis (MS) patients may also be at risk of the disease and its complications depending on the medication they are taking. In this study, we evaluated a large population of patients with MS with different disease modifying drugs to show if any of them increases the risk. In addition, this study evaluates the incidence of COVID-19 in patients with MS, the rate of hospitalization or death in these patients. METHOD: This study was performed at the MS Clinic of Sina Hospital. All patients were contacted and their demographic characteristics were recorded. They were then asked about their COVID-19 symptoms. Patients with these symptoms were further evaluated. The documents were reviewed by treating neurologist and MS nurses to be sure about diagnosis of COVID19. The positive polymerase chain reaction (PCR) result or compatible lung computed tomography (CT) scan was acceptable for COVID-19 diagnosis. RESULTS: 4647 patients answered the phone contact. Of these, 66 were infected with the COVID-19. The rate of hospitalization was 25% which is far more than general population. Two patients died from COVID-19. Rituximab was associated with increase rate of COVID-19 infection but not with hospitalization rate. There was no significant correlation between use of other drugs and rate of infection. CONCLUSION: This study revealed that the incidence of COVID-19 in MS patients is not more than general population, but the risk of hospitalization in these patients is higher than estimated for the disease. This highlights the importance of communicating to patients the severity of COVID-19 and the importance of risk reduction behaviors like social distancing and mask use. Multiple sclerosis (MS) is an autoimmune disease that can cause a variety of symptoms by affecting the central nervous system (CNS). In this disease, two phenomena of inflammation and neurodegeneration occur simultaneously, which complicate the manifestation of the disease (1). Most drugs affect the inflammatory phase of the disease and can only indirectly reduce neurodegeneration (2) . Due to the progressive nature of the disease, several drugs have been introduced to treat it. Since the introduction of the first MS drug in 1993 (3), all efforts have been made to develop more potent drugs. Although the primary used drugs were immunomodulatory, immunosuppressive drugs were gradually preferred due to their high efficacy and very positive results (4) . Despite their high effectiveness, these drugs can expose patients to various infections due to their immunosuppressive effect. Studies have shown that drugs such as rituximab, alemtuzumab, and fingolimod increase the risk of infectious diseases (5) . Therefore, paying attention to these complications and preventing them is very important in the treatment of MS patients, and care should always be taken to avoid possible infections due to the use of these medications. One of the infectious diseases that is highly regarded these days and affects the treatment of MS patients is COVID-19 (6) . The disease is caused by the SARS-CoV-2, which was first reported in December 2019 in Wuhan, China (7) . It has increasingly involved individuals and has caused mortality. In general, people who have an underlying disease or are taking immunosuppressive drugs are more likely to be infected. The same concern applies to COVID-19 and its impact on a wide range of diseases. A large number of diseases require the use of immunosuppressive drugs for better control. MS also needs high-potency drugs due to its pathophysiology and progressive nature, which also weaken the immune system. Therefore, the question then arises of how much MS patients are at risk of COVID-19 and its complications due to their underlying disease and the use of a wide range of drugs. To date, some reports of MS patients infected with the disease have been published (8) (9) (10) (11) (12) . The preliminary studies suggested that CD20-depeleting monoclonal antibodies may expose people to increased risk of developing COVID-19 (8) . Here, we have studied a larger population of patients with MS with different disease modifying therapies to determine whether this risk was still evident. This study examines the rate of diagnosis of COVID-19 as well as the rate of hospitalization and prognosis in MS patients. In addition, our study assesses these ratios using a larger sample size and different patients from previous report from Iran (8) . The study was performed at the MS Clinic of Sinai Hospital from 5 -25 May, 2020. MS patients of this clinic are registered in its registry system. Therefore, the demographic characteristics of all patients, including age, gender, disease duration, medication, and type of MS were extracted from the registry system. All of these patients were contacted and asked about COVID-19 disease. Most contacts were made by phone and not in person. In some patients, multiple attempts to contact them were made. Those who came to the clinic for a routine visit during this time were interviewed in person. The calls were made by 10 people. All of them asked patients the same specific questions about the COVID-19 disease. In addition, more detailed information regarding patients infected by COVID-19 was obtained from their medical reports. The information of patients who were hospitalized and could not respond to the call or had died prior to contact was obtained from their relatives. Additional data were obtained from all patients who responded positively, such as the symptoms of the COVID-19 disease, the characteristics of the computed tomography (CT) scan of the lungs, the polymerase chain reaction (PCR) test, and the medications used for COVID-19. Also, hospitalization, duration of hospitalization, and its final result were recorded. To be more precise, patients were asked to submit all documents related to the infection, including tests, PCR results, and CT scans of the lungs. These documents were reviewed by treating neurologist and MS nurses to be sure about diagnosis of COVID19. The positive PCR result or compatible lung CT scan was acceptable for COVID-19 diagnosis. Data are expressed as mean ± SD for quantitative variables and counts (%) for categorical variables. We used SPSS 21 (SPSS, Chicago, IL, USA) for the statistical analysis of data. Between-group differences were analyzed by Student's t-test for quantitative variables. The association of categorical variables were tested by Chi-Square or Fisher's Exact tests, where indicated. Logistic regression was performed for estimation of odds ratio. From all the calls and interviews (5012 registered patients), 4647 patients (77.94% female) answered the questions ( Table 1 ). The mean age of patients was 36.84 ±9.21. 68 patients (1.46%) had been diagnosed as COVID-19 and the mean age of COVID-19 patients was 37.27±9.10. Overall, 25% of them had been hospitalized. Two patients (2.94%), who both were receiving rituximab, died during COVID-19 pandemic. They had underlying diseases; the first patient suffered from Sjögren's syndrome and hypothyroidism simultaneously, and the second patient suffered from morbid obesity. in the general population (13 & 14) . Another study also did not show an increase in the risk of COVID-19 in MS patients compared to the general population; of 1804 patients with MS, none had COVID-19 (9) . The reason why the rate of infection with COVID-19 in these patients is not more than general population, despite initial predictions (i.e., higher probability of involvement due to the use of immunosuppressive drugs), is probably because these patients pay more attention to health tips. According to a study conducted in Iran on 100 patients, these patients had a good knowledge of COVID-19 and factors related to its prevalence, and were aware of the importance of following medical advice (15) . In addition, young age of MS patients, their female gender, and the low incidence of comorbidities in these patients can justify the low risk of developing COVID-19 (16) . Moreover, it should be noted that MS drugs are not particularly targeting the biology important to viral elimination (innate immune system) and do not influence the vascular pathology that is central to COVID-19 pathophysiology (17) . Furthermore, some medications especially interferons have anti-viral effect and can attenuate the symptoms of COVID-19 in these patients (18) . The present study indicated that the use of rituximab increases the risk of developing COVID-19. This was not documented in the study of Fan et al (9) . However, in another study in Iran, 712 patients with MS filled out a questionnaire about COVID-19 symptoms, of which 34 patients (4.8%) had COVID-19 symptoms. It was indicated that the use of B-cell depletion drugs can increase the risk of COVID-19 (8) , which is consistent with our findings. Increase in the risk of COVID-19 through B-cell depleting therapies was expected. Previous studies have all confirmed an increased risk of infection in inpatients consuming these drugs (19) . Increase in the risk of other infections following the use of these drugs correlates with the increase in the risk of developing COVID-19 through using these drugs (20) . However, we find that this risk did not increase with interferons, glatiramer acetate and oral therapies. Another noticeable finding of our study was the high proportion of patients receiving natalizumab infected by COVID-19. The rate of hospitalization in our patients is 25%, which is much higher than the global statistics in the general population. Although the rate of hospitalization varies with age and underlying disease, the rate has been reported to be 3.4% -4.3% for the age group associated with MS patients (21) . This finding is in agreement with previous studies. Parrotta et el. have reported a high frequency of hospitalization (9/34 (26.4%)) following CD20 treatment (22) . This has been seen in some cohorts treated with rituximab in Sweden (9/41 (22%)) (Hillert J. iWiMS MS Covid-19. 20 May 2020 (https://youtu.be/z4sRBQEv0yE)); France (9/17 (52.9%)) (12), and with ocrelizumab in France (10/38 (26.3%)) (12), the USA (23) and in a ocrelizumab pharmacovigilance study ( disease. However, the authors did not mention anything about the patient's comorbidities (28). In the current study, although the rate of hospitalization was not related to the type of medication, the two patients who died both were rituximab users. They also had underlying diseases; the first patient suffered from Sjögren's syndrome and hypothyroidism simultaneously, and the second patient suffered from morbid obesity. Nevertheless, the mortality rate in the present study was 2.9%, which is line with global statistics in normal population (29 & 30) . However, the extent to which rituximab was involved in the deaths of these two patients requires further research. It 2-Rituximab depletes B cells and so inhibits the capacity to produce immunoglobulins to new antigens. IgM and IgA have been suggested to be part of the defence mechanism and so this will be inhibited (17). 3-Rituximab induces IgA, IgG and marked IgM hypogammaglobulinemia, which are known risk factors for serious infections (17) . As immunity to COVID-19 is in part supported by cross-reactive immunity to cold-causing coronavirus (17, 33, 35) , CD20depletion may have limited the production of protective antibody formation during past coronavirus infections 4-Alternatively hypogammaglobulinemia could limit protective antibody responses that have formed and so reduce protection from infection. It should be noticed that all of the mentioned explanation must be studied in further investigations. The type of MS was also found to be associated with the risk of developing COVID-19, and its development was significantly more common among RRMS patients. This can be due to the better physical condition of these patients and the possibility of their greater presence in the community, as they do their personal affairs and job that may expose them to the disease. The present study demonstrated that MS patients are not more likely to develop COVID-19 than general population. However, it was shown that they are more likely to be hospitalized than general population. This highlights the importance of communicating to patients the severity of COVID-19 and the importance of risk reduction behaviors like social distancing and mask use. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function Induction or escalation therapy for patients with multiple sclerosis? Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study The COVID-19 pandemic and the use of MS disease-modifying therapies A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence Naser Moghadasi A. Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran Rethinking high-risk groups in COVID-19 The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 Estimates of the severity of coronavirus disease 2019: a model-based analysis COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection COVID-19 in persons with multiple sclerosis treated with ocrelizumab -A pharmacovigilance case series Infections in patients with multiple sclerosis: Implications for diseasemodifying therapy Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis Characteristics of COVID-19 disease in multiple sclerosis patients Real estimates of mortality following COVID-19 infection Estimating case fatality rates of COVID-19 COVID-19 pathophysiology: A review Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals